Skip to main content

Eye Matters

Intraocular pressure---Glaucoma

As new aqueous flows into your eye, balancing amount should drain out. This process maintains pressure in your eye balanced. But if the fluid builds up because of several reasons, pressure inside the eye called introcular pressure increases resulting in the optic nerve damage. 

Glaucoma medications:


Prostaglandin analogs increase the drainage of fluid from the eye. These include:

1. Xalatan® (latanoprost), 
2. Travatan Z® (Travoprost), 
3. Lumigan® (bimatoprost), and 
4. Zioptan™ (tafluprost). 

Beta blockers such as timolol are the second most often used class of medications that work by decreasing production of fluid. 

Alpha agonists decreases production of fluid and increases drainage.

1. [Alphagan®P (brimonidine), Iopidine®] 
2. Alphagan P has a purite preservative that breaks down into natural tear components and may be better tolerated in patients allergic to preservatives.

Carbonic anhydrase inhibitors (CAIs) decrease the production of intraocular fluid. These are available as 
Eye drops 
1. Trusopt® (dorzolamide), 
2. Azopt® (brinzolamide)] 

Oral capsules:
1. Diamox (acetazolamide) and
2. Neptazane® (methazolamide). 
Except for Azopt, all CAIs are available in generic form.

Combined medications are available for patients who need more than one type of medication. 1. Cosopt® contains a combination of a beta blocker (timolol) and a carbonic anhydrase inhibitor (dorzolamide) and is available in generic form and also as a preservative-free formulation (Cosopt® PF). 

2. Combigan® an alpha agonist (brimonidine) with a beta blocker (timolol). Simbrinza® is a beta blocker-free combination medication, It has brinzolamide and brimonidine.


Point 1: 

Travoprost (0.0015% and 0.004%), a highly selective, potent prostaglandin F receptor agonist, is equal or superior to latanoprost and superior to timolol in lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, travoprost 0.004% is significantly better than either latanoprost or timolol in lowering intraocular pressure in black patients. Travoprost is safe and generally well tolerated in the studied patient population. ( 2001 Oct;132(4):472-84.)

Point 2: 

Mean IOP changes from baseline for travoprost 0.004% and latanoprost 0.005%/timolol 0.5% fixed combination were not significantly different at follow-up in these patients. Both medications were well tolerated. ( 2006 Mar;28(3):332-9.)

Comments

  1. I am heartily thankful to you for sharing this best knowledge. This information is helpful for everyone. So please always share this kind of knowledge. Thanks once again for sharing it. Mental health services in Madera, CA

    ReplyDelete

Post a Comment

Popular posts from this blog

Sodium chloride Tablets USP

A 91- year old patient. Admitted to the hospital from the ED. Patient was seen for altered mental status. Labs, CT of brain head, CXR XR of left Tib/Fib were performed. Presumed meningioma in the left middle cranial fossa was noted. Sodium was critically low at 114. Nephrologist was consulted and hyponatremia is of unknown etiology. Patient also has uncontroled hypertension. Comorbidities: Coronary artery disease, Diabetes, Dementia, hypothyroidism, hyperlipedemia, neuropathy. Patient will need physicain oversight for hyponatremia, normal saline routinely, and medication management for hypertension. Rx: Sodium Chloride USP 1.0 gram Use  1. Hyponatremia 2. Preparation of normal isotonic solution of sodium chloride 3. As an electrolyte replenisher for the prevention of heat cramps, due to excessive  perspiration 4. any alternate use as directed by a physician Each tablet contains: sodium 394mg Hyponatremia  is a common electrolyte disorder encountered i...

Mounjaro, Is it a game changer for weight loss and diabetes?

  MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is  finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2  Known serious all to tirzepatide or any of the excipients in MOUNJARO                                                                    ...

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk.   In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk (  Andrus & Lacaille, 2014  )  The guideline classifies statin therapy as  high-intensity (lowers LD...